FDA Approves BESREMi Pen for Self-Administration in Polycythemia Vera

PharmaEssentia USA Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved the BESREMi Pen (ropeginterferon alfa-2b-njft).

This new pre-filled pen device is indicated for adult patients with polycythemia vera (PV) and is designed to enhance the patient experience by simplifying the process of self-administration. For oncology nurses, this approval represents a shift toward more intuitive chronic care management. The device offers a more convenient alternative to the previously available pre-filled syringe, potentially reducing the barriers to treatment consistency.

Advancing care in polycythemia vera

Polycythemia vera is a rare, chronic blood cancer originating from disease-initiating stem cells in the bone marrow. The condition is characterized by a persistent increase in red blood cells, white blood cells, and platelets, which significantly elevates the risk of cardiovascular complications such as thrombosis and embolism. Without proper management, PV can progress to secondary myelofibrosis or leukemia. While research into the molecular mechanisms continues, the presence of the JAK2 mutation remains a primary clinical marker for the disease.

BESREMi, a long-acting interferon, has held orphan drug designation in the United States and has already been approved in more than 40 countries, including the European Union and Japan. The introduction of the pen delivery system aims to empower patients to manage this complex condition with greater ease.

Clinical significance and patient adherence

The transition from a syringe to a pen-based delivery system is often a critical factor in patient adherence for injectable therapies. Dr. John Mascarenhas, Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at Mount Sinai, emphasized that treatment consistency is vital for PV management in a statement included in a news release detailing the approval.

"This device has the potential to make a meaningful positive impact on patients' lives by simplifying self-administration and supporting better adherence," Mascarenhas noted.

For nursing professionals, the pen device may simplify the education process for newly diagnosed patients or those transitioning from other therapies. The design is intended to build patient confidence in managing their long-term care at home.

Nursing considerations: monitoring and safety

Despite the increased convenience of the delivery system, the safety profile of ropeginterferon alfa-2b-njft requires vigilant nursing oversight. The agent carries a boxed warning regarding the risk of serious disorders, including neuropsychiatric, autoimmune, ischemic, and infectious conditions.

Oncology nurses should prioritize the following monitoring parameters for patients utilizing the BESREMi Pen:

• Neuropsychiatric Symptoms: Monitor for depression, suicidal ideation, or other mood changes.
• Hematologic Evaluation: Blood counts should be performed at baseline, every two weeks during the titration phase, and every three to six months during maintenance.
• Organ Toxicity: Regular evaluation of hepatic and renal function (serum creatinine) is required. Patients should also be monitored for signs of pancreatitis, colitis, and pulmonary toxicity.
• Endocrine and Cardiovascular Health: Nurses should monitor for thyroid dysfunction and cardiovascular events, particularly in patients with a history of unstable cardiac disease.

Patients should also be advised on the importance of regular dental examinations and eye exams to monitor for periodontal and ophthalmologic toxicities.

Availability

The BESREMi Pen is expected to become commercially available in the United States in the coming weeks. As PharmaEssentia continues to expand its presence, the company is also seeking label expansion for ropeginterferon alfa-2b-njft to include essential thrombocythemia (ET).

Reference

PharmaEssentia. PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera. News release. June 26, 2026. Accessed June 26, 2026.